A Phase 1 Study to Evaluate the Safety and Immunogenicity of a Recombinant HIV Type 1 Subtype C-Modified Vaccinia Ankara Virus Vaccine Candidate in Indian Volunteers-Reference-Cited by-同舟云学术

A Phase 1 Study to Evaluate the Safety and Immunogenicity of a Recombinant HIV Type 1 Subtype C-Modified Vaccinia Ankara Virus Vaccine Candidate in Indian Volunteers

Published:2009-11 Issue:11 Volume:25 Page:1107-1116
ISSN:0889-2229
Container-title:AIDS Research and Human Retroviruses
language:en
Short-container-title:AIDS Research and Human Retroviruses

Author:

Ramanathan Vadakkuppatu Devasenapathi¹,Kumar Makesh¹,Mahalingam Jayashri¹,Sathyamoorthy Pattabiraman¹,Narayanan Paranji Ramaiyengar¹,Solomon Suniti²,Panicali Dennis³,Chakrabarty Sekhar⁴,Cox Josephine⁵,Sayeed Eddy⁵,Ackland James⁵,Verlinde Carl⁵,Vooijs Dani⁵,Loughran Kelley⁶,Barin Burc⁶,Lombardo Angela⁵,Gilmour Jill⁷,Stevens Gwynneth⁸,Smith Michelle Seth⁹,Tarragona-Fiol Tony⁹,Hayes Peter⁹,Kochhar Sonali¹⁰,Excler Jean-Louis⁵,Fast Patricia⁵

Affiliation:

1. Tuberculosis Research Centre, Chennai, India.

2. YRG Care, Chennai, India.

3. Acton, Massachusetts 01720.

4. National Institute of Cholera and Enteric Diseases, Kolkata, India.

5. International AIDS Vaccine Initiative, New York, New York 10038.

6. EMMES Corporation, Rockville Maryland 20850.

7. IAVI Human Immunology Laboratory, Imperial College, London, UK.

8. IAVI Southern Africa, Johannesburg, South Africa.

9. Imperial College, London, UK.

10. International AIDS Vaccine Initiative, New Delhi, India.

Publisher